Lung carcinoma, pleural malignancy and thymic tumours

Han, S. (2022) Lung carcinoma, pleural malignancy and thymic tumours. In: Evidence-Based Indications for the Use of PET-CT in the United Kingdom 2022. Royal College of Radiologists: London, pp. 9-12.

Full text not currently available from Enlighten.

Publisher's URL: https://www.rcr.ac.uk/publication/evidence-based-indications-use-pet-ct-united-kingdom-2022

Abstract

A document prepared for the Intercollegiate Standing Committee on Nuclear Medicine, by members of The Royal College of Radiologists and the Royal College of Physicians. Lead authors (for current edition): Sabina Dizdarevic, Andrew Scarsbrook, Sally Barrington. List of co-authors and contributors (for current edition) *: Asim Afaq, Parthiban Arumugam, Tara Barwick, Clare Beadsmoore, Lorenzo Biassoni, Jamshed Bomanji, John Buscombe, Amarnath Challapalli, Greg Chambers, Gary Cook, Stephen Daw, Amy Eccles, Sameer Gangoli, Gopinath Gnanasegaran, Deepa Gopalan, Richard Graham, Prasad Guntur, Sai Han, Athar Haroon, Iain Lyburn, Sergejs Magers, Vanessa Morris, Shaunak Navalkissoor, Bob Philips, Eliana Reyes, Rebecca Roylance, Ananth Shankar, Nitasha Singh, Teresa Szyszko, Sharlini Varatharajah, Sobhan Vinjamuri, Stefan Vöö, Kshama Wechalekar, Zarni Win, Wai Lup Wong, Lyn Zimmo. These guidelines comprise an up-to-date summary of relevant indications for the use of PET-CT, where there is good evidence that patients will benefit from improved disease assessment resulting in altered management and improved outcomes. This document supersedes the previous ‘Evidence-based indications for the use of PET-CT in the United Kingdom’ guidelines published by The Royal College of Radiologists in 2016. The document will be updated at regular intervals. The indications are divided into oncological and non-oncological applications then body area/system. This list is not exhaustive and there are cases where PET-CT may be helpful in patients who have equivocal or definite abnormalities on other imaging where PET-CT may alter the management strategy if found to be ‘positive’ or ‘negative’; for example, radical or high-risk surgery. PET-CT would be appropriate in such patients at the discretion of the local Administration of Radioactive Substances Advisory Committee (ARSAC) licence holder as a problem-solving tool when other imaging modalities have been inconclusive.

Item Type:Book Sections
Status:Published
Glasgow Author(s) Enlighten ID:Han, Dr Sai
Authors: Han, S.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Publisher:Royal College of Radiologists

University Staff: Request a correction | Enlighten Editors: Update this record